Similarly, inhibitors targeting the IL-6 pathway, like tocilizumab, have entered clinical trials to evaluate their potential in mitigating cancer-related inflammation and cachexia, showcasing the therapeutic versatility of targeting cytokine pathways. Here, IL6 is linked to cancer.